BIAF has been in the news 643% more than usual
Mar 17, 2026, 12:33 PM
50.66%
What does BIAF do
bioAffinity Technologies, based in San Antonio, Texas, focuses on non-invasive early-stage cancer diagnosis and treatment, employing 75 staff since its IPO on August 26, 2022. Its first product, CyPath Lung, aids in detecting early-stage lung cancer, enhancing patient intervention decisions.
BIAF has been in the news recently: BioAffinity Technologies reported a 20% increase in quarterly profits, driven by strong sales growth and favorable market conditions. Additionally, the company experienced a 15% rise in revenue, reflecting its successful sales performance in the last quarter.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.